Drug Trial Radar · NCT06927739
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
240
Planned (sponsor's estimate)
Start
Aug 11, 2025
Primary completion
Feb 8, 2027
Study completion Jun 1, 2027
Sponsor
- Lead sponsor
- AbcentraIndustry
- Sponsor type
- Industry
- First posted
- Apr 15, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is: Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA Researchers will compare the effects with placebo group after 6 months of treatment Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies
Conditions
- Acute Coronary Syndromes
- Coronary Arterial Disease (CAD)
- Inflammation
- Heart Disease
- Myocardial Infarct
- Atherosclerotic Coronary Vascular Disease
Interventions
OrticumabDrug
Orticumab treatment for 24 weeks for post MI population
PlaceboDrug
Placebo for 24 weeks for the post MI population
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline of the mean Fat Attenuation Index (FAI) score for the 3 coronary arteries (RCA, LAD and LCX) for orticumab compared to placebo at 24 weeksTime frame: 24 weeks
Locations
41 sites in 9 countries. Site status is shown where the registry gives one.
Abcentra Investigational Site
Los Angeles, California · Not yet recruiting
Abcentra Investigational Site
Torrance, California · Recruiting
Abcentra Investigational Site
Boca Raton, Florida · Recruiting
Abcentra Investigational Site
Richmond, Indiana · Recruiting
Abcentra Investigational Site
Louisville, Kentucky · Not yet recruiting
Abcentra Investigational Site
Baltimore, Maryland · Recruiting
Abcentra Investigational Site
Midland, Michigan · Recruiting
Abcentra Investigational Site
Ostrava, Moravian-Silesian Region, Czechia · Recruiting
Abcentra Investigational Site
Pilsen, Plzeň Region, Czechia · Recruiting
Abcentra Investigational Site
Prague, Praha 2, Czechia · Recruiting
Abcentra Investigational Site
Prague, Praha 4, Czechia · Recruiting
Abcentra Investigational Site
Brno, South Moravian, Czechia · Recruiting
Abcentra Investigational Site
Pécs, Baranya, Hungary · Recruiting
Abcentra Investigational Site
Budapest, Central Hungary, Hungary · Recruiting
Abcentra Investigational Site
Budapest, Central Hungary, Hungary · Recruiting
Abcentra Investigational Site
Budapest, Central Hungary, Hungary · Recruiting
Abcentra Investigational Site
Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary · Recruiting
Abcentra Investigational Site
Caserta, Campania, Italy · Recruiting
Abcentra Investigational Site
Ferrara, Ferrara, Italy · Recruiting
Abcentra Investigational Site
Brescia, Lombardy, Italy · Recruiting
Abcentra Investigational Site
Milan, Lombardy, Italy · Recruiting
Abcentra Investigational Site
Pavia, Lombardy, Italy · Recruiting
Abcentra Investigational Site
Krakow, Lesser Poland Voivodeship, Poland · Recruiting
Abcentra Investigational Site
Wroclaw, Lower Silesian Voivodeship, Poland · Recruiting
Abcentra Investigational Site
Warsaw, Masovian Voivodeship, Poland · Recruiting
Abcentra Investigational Site
Baia Mare, Maramureş, Romania · Recruiting
Abcentra Investigational Site
Târgu Mureş, Mureș County, Romania · Recruiting
Abcentra Investigational Site
Timișoara, Timiș County, Romania · Recruiting
Abcentra Investigational Site
Córdoba, Andalusia, Spain · Recruiting
Abcentra Investigational Site
Madrid, Madrid, Spain · Recruiting
Abcentra Investigational Site
Madrid, Madrid, Spain · Recruiting
Abcentra Investigational Site
El Palmar, Murcia, Spain · Recruiting
Abcentra Investigational Site
Seville, Sevilla, Spain · Recruiting
Abcentra Investigational Site
Danderyd, Stockholm County, Sweden · Recruiting
Abcentra Investigational Site
Solna, Stockholm County, Sweden · Recruiting
Abcentra Investigational Site
Gothenburg, Västra Götaland County, Sweden · Recruiting
Abcentra Investigational Site
London, Greater London, United Kingdom · Recruiting
Abcentra Investigational Site
Manchester, Greater Manchester, United Kingdom · Recruiting
Abcentra Investigational Site
Oxford, Oxfordshire, United Kingdom · Recruiting
Abcentra Investigational Site
Bath, Somerset, United Kingdom · Recruiting
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.